Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

Unraveling the potential of hypothalamic deep brain stimulation for obesity: Impacts on memory, neuroplasticity and brain metabolism in the Zucker rat

  • Casquero-Veiga, Marta
  • Llorca Torralba, Meritxell
  • Bueno-Fernandez, C.
  • Romero-Miguel, Diego
  • Lamanna-Rama, Nicolás
  • Winter, C.
  • Berrocoso Domínguez, Esther María
  • Nacher, Juan
  • Desco, Manuel
  • Soto-Montenegro, María Luisa
The lateral hypothalamus (LH) plays a key role in regulating energy balance and appetite, making it a potential target for deep brain stimulation (DBS) in treatment-resistant obesity. In this study, we evaluated the short and long-term in vivo effects of continuous LH-DBS over 15 days in a genetic model of obesity: the Zucker rat. We examined changes in body weight, brain glucose metabolism (via positron emission tomography, PET), and memory performance, along with ex vivo neuroplasticity in different hippocampal layers one month post-treatment. Contrary to expectations, continuous LH-DBS did not reduce the weight gain or food intake. While stimulated rats exhibited hippocampal hypermetabolism and enhanced synaptogenesis, these changes did not translate into cognitive improvements. Interestingly, long-term memory benefits were observed in all animals that underwent surgery, regardless of whether they received stimulation. In conclusion, our results do not support continuous LH-DBS as an effective treatment to reduce body weight in cases of obesity with genetic leptin resistance. However, the hippocampal modulation induced by continuous LH-DBS shows potential for addressing cognitive impairments associated with leptin resistance. These findings suggest that alternative DBS protocols may help restore hippocampal function, warranting further investigation.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

A Characterization of the Effects of Minocycline Treatment During Adolescence on Structural, Metabolic, and Oxidative Stress Parameters in a Maternal Immune Stimulation Model of Neurodevelopmental Brain Disorders

  • Romero-Miguel, Diego
  • Casquero-Veiga, Marta
  • MacDowell, Karina S.
  • Torres Sánchez, Sonia
  • García Partida, José Antonio
  • Lamanna-Rama, Nicolás
  • Romero-Miranda, Ana
  • Berrocoso Domínguez, Esther María
  • Leza, Juan Carlos
  • Desco, Manuel
  • Soto-Montenegro, María Luisa
Background: Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested an early therapeutic window, during adolescence, as prevention of the schizophrenia-related deficits in the maternal immune stimulation (MIS) animal model. Methods: On gestational day 15, Poly I:C or vehicle was injected in pregnant Wistar rats. A total 93 male offspring received MIN (30 mg/kg) or saline from postnatal day (PND) 35-49. At PND70, rats were submitted to the prepulse inhibition test. FDG-PET and T2-weighted MRI brain studies were performed at adulthood. IOS markers were evaluated in frozen brain tissue. Results: MIN treatment did not prevent prepulse inhibition test behavioral deficits in MIS offspring. However, MIN prevented morphometric abnormalities in the third ventricle but not in the hippocampus. Additionally, MIN reduced brain metabolism in cerebellum and increased it in nucleus accumbens. Finally, MIN reduced the expression of iNOS (prefrontal cortex, caudate-putamen) and increased the levels of KEAP1 (prefrontal cortex), HO1 and NQO1 (amygdala, hippocampus), and HO1 (caudate-putamen). Conclusions: MIN treatment during adolescence partially counteracts volumetric abnormalities and IOS deficits in the MIS model, likely via iNOS and Nrf2-ARE pathways, also increasing the expression of cytoprotective enzymes. However, MIN treatment during this peripubertal stage does not prevent sensorimotor gating deficits. Therefore, even though it does not prevent all the MIS-derived abnormalities evaluated, our results suggest the potential utility of early treatment with MIN in other schizophrenia domains., M.L.S. was supported by the Ministerio de Ciencia, Innovacion y Universidades, Instituto de Salud Carlos III (projects PI14/00860 and PI17/01766, and grant CPII14/00005), co-financed by European Regional Development Fund (ERDF), "A way of making Europe", CIBER of Mental Health (CIBERSAM), Delegacion del Gobierno para el Plan Nacional sobre Drogas (2017/085), Fundacion Mapfre and Fundacion Alicia Koplowitz. M.C.-V. was supported by Fundacion Tatiana Perez de Guzman el Bueno. D.R.-M. was supported by Consejeria de Educacion e Investigacion, Comunidad de Madrid, co-funded by European Social Fund "Investing in your future" (grant, PEJD-2018-PRE/BMD-7899). N.L.-R. was supported by Instituto de investigacion Sanitaria Gregorio Maranon. A.R.-M. was supported by Consejeria de Educacion e Investigacion, Comunidad de Madrid, co-funded by European Social Fund "Investing in your future" (grant, PEJ15/BIO/TL-0216). The CNIC was supported by the Spanish Ministerio de Ciencia, Innovacion y Universidades (MCIU) and the Pro-CNIC Foundation. J.C.L. was supported by the Spanish Ministry of Economy, Industry and Competitiveness (MINECOEU-FEDER) SAF2016-75500-R and CIBERSAM. E.B.D., S.T.-S., and J.A.G.-P. were supported by grants: co-financed by the "Fondo Europeo de Desarrollo Regional" (FEDER)-UE "A way to build Europe" from the "Ministerio de Economia y Competitividad" (MINECO: RTI2018-099778-B-I00) and the "Ministerio de SaludInstituto de Salud Carlos III (PI18/01691); from the "Plan Nacional sobre Drogas, Ministerio de Sanidad, Consumo y Bienestar Social" (2019I041); from the "Programa Operativo de Andalucia FEDER, Iniciativa Territorial Integrada ITI 2014-2020 Consejeria Salud, Junta de Andalucia" (PI-0080-2017 and PI-0009-2017); from the Consejeria de Salud de la Junta de Andalucia (PI-0134-2018); from the University of Cadiz (PR2019-046); from the "Instituto de Investigacion e Innovacion en Ciencias Biomedicas de Cadiz-INiBICA" (IN-C22; LI19/06IN-CO22); from the "Consejeria de Economia, Innovacion, Ciencia y Empleo de la Junta de Andalucia" (CTS-510); from the "CIBERSAM" (CB/07/09/0033).
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

The effects of mango leaf extract during adolescence and adulthood in a rat model of schizophrenia

  • García Partida, José Antonio
  • Torres Sánchez, Sonia
  • MacDowell, Karina S.
  • Fernández Ponce, María Teresa
  • Casas Cardoso, Lourdes
  • Mantell Serrano, Casimiro
  • Soto-Montenegro, María Luisa
  • Romero-Miguel, Diego
  • Lamanna-Rama, Nicolás
  • Leza, Juan Carlos
  • Desco, Manuel
  • Berrocoso Domínguez, Esther María
There is evidence that in schizophrenia, imbalances in inflammatory and oxidative processes occur during pregnancy and in the early postnatal period, generating interest in the potential therapeutic efficacy of anti-inflammatory and antioxidant compounds. Mangiferin is a polyphenolic compound abundant in the leaves of Mangifera indica L. that has robust antioxidant and anti-inflammatory properties, making it a potential candidate for preventive or co-adjuvant therapy in schizophrenia. Hence, this study set-out to evaluate the effect of mango leaf extract (MLE) in a model of schizophrenia based on maternal immune activation, in which Poly I:C (4 mg/kg) is administered intravenously to pregnant rats. Young adult (postnatal day 60-70) or adolescent (postnatal day 35-49) male offspring received MLE (50 mg/kg of mangiferin) daily, and the effects of MLE in adolescence were compared to those of risperidone, assessing behavior, brain magnetic resonance imaging (MRI), and oxidative/inflammatory and antioxidant mediators in the adult offspring. MLE treatment in adulthood reversed the deficit in prepulse inhibition (PPI) but it failed to attenuate the sensitivity to amphetamine and the deficit in novel object recognition (NOR) induced. By contrast, adolescent MLE treatment prevented the sensorimotor gating deficit in the PPI test, producing an effect similar to that of risperidone. This MLE treatment also produced a reduction in grooming behavior, but it had no effect on anxiety or novel object recognition memory. MRI studies revealed that adolescent MLE administration partially counteracted the cortical shrinkage, and cerebellum and ventricle enlargement. In addition, MLE administration in adolescence reduced iNOS mediated inflammatory activation and it promoted the expression of biomarkers of compensatory antioxidant activity in the prefrontal cortex and hippocampus, as witnessed through the reduction of Keap1 and the accumulation of NRF2 and HO1. Together, these findings suggest that MLE might be an alternative therapeutic or preventive add-on strategy to improve the clinical expression of schizophrenia in adulthood, while also modifying the time course of this disease at earlier stages in populations at high-risk.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publication Artículo científico (JournalArticle)

N-acetylcysteine during critical neurodevelopmental periods prevents behavioral and neurochemical deficits in the Poly I:C rat model of schizophrenia

  • Romero-Miguel, D.
  • Casquero-Veiga, M.
  • Lamanna-Rama, N.
  • Torres Sánchez, Sonia
  • MacDowell, K.S.
  • García Partida, José Antonio
  • Santa-Marta, C.
  • Berrocoso Domínguez, Esther María
  • Leza, J.C.
  • Desco, M.
  • Soto-Montenegro, M.L.
Schizophrenia is a chronic neurodevelopmental disorder with an inflammatory/prooxidant component. N-acetylcysteine (NAC) has been evaluated in schizophrenia as an adjuvant to antipsychotics, but its role as a preventive strategy has not been sufficiently explored. We aimed to evaluate the potential of NAC administration in two-time windows before the onset of symptoms in a schizophrenia-like maternal immune stimulation (MIS) rat model. Pregnant Wistar rats were injected with Poly I:C or Saline on gestational day (GD) 15. Three different preventive approaches were evaluated: 1) NAC treatment during periadolescence in the offspring (from postnatal day [PND] 35 to 49); 2) NAC treatment during pregnancy after MIS challenge until delivery (GD15–21); and 3) NAC treatment throughout all pregnancy (GD1–21). At postnatal day (PND) 70, prepulse inhibition (PPI) and anxiety levels were evaluated. In vivo magnetic resonance (MR) imaging was acquired on PND100 to assess structural changes in gray and white matter, and brain metabolite concentrations. Additionally, inflammation and oxidative stress (IOS) markers were measured ex vivo in selected brain regions. MIS offspring showed behavioral, neuroanatomical, and biochemical alterations. Interestingly, NAC treatment during periadolescence prevented PPI deficits and partially counteracted some biochemical imbalances. Moreover, NAC treatments during pregnancy not only replicated the beneficial outcomes reported by the treatment in periadolescence, but also prevented some neuroanatomical deficits, including reductions in hippocampal and corpus callosum volumes. This study suggests that early reduction of inflammation and prooxidation could help prevent the onset of schizophrenia-like symptoms, supporting the importance of anti-IOS compounds in ameliorating this disorder., 15 páginas
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Maternal Supplementation with N-Acetylcysteine Modulates the Microbiota-Gut-Brain Axis in Offspring of the Poly I:C Rat Model of Schizophrenia

  • Romero-Miguel, Diego
  • Casquero-Veiga, Marta
  • Fernández, Javier
  • Lamanna-Rama, Nicolas
  • Gómez-Rangel, Vanessa
  • Gálvez-Robleño, Carlos
  • Santa-Marta, Cristina
  • Villar, Claudio J.
  • Lombó, Felipe
  • Abalo, Raquel
  • Desco, Manuel
  • Soto-Montenegro, María Luisa
The microbiota-gut-brain axis is a complex interconnected system altered in schizophrenia. The antioxidant N-acetylcysteine (NAC) has been proposed as an adjunctive therapy to antipsychotics in clinical trials, but its role in the microbiota-gut-brain axis has not been sufficiently explored. We aimed to describe the effect of NAC administration during pregnancy on the gut-brain axis in the offspring from the maternal immune stimulation (MIS) animal model of schizophrenia. Pregnant Wistar rats were treated with PolyI:C/Saline. Six groups of animals were studied according to the study factors: phenotype (Saline, MIS) and treatment (no NAC, NAC 7 days, NAC 21 days). Offspring were subjected to the novel object recognition test and were scanned using MRI. Caecum contents were used for metagenomics 16S rRNA sequencing. NAC treatment prevented hippocampal volume reduction and long-term memory deficits in MIS-offspring. In addition, MIS-animals showed lower bacterial richness, which was prevented by NAC. Moreover, NAC7/NAC21 treatments resulted in a reduction of proinflammatory taxons in MIS-animals and an increase in taxa known to produce anti-inflammatory metabolites. Early approaches, like this one, with anti-inflammatory/anti-oxidative compounds, especially in neurodevelopmental disorders with an inflammatory/oxidative basis, may be useful in modulating bacterial microbiota, hippocampal size, as well as hippocampal-based memory impairments., M.L.S.-M. was supported by the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III (project number PI17/01766, and grant number BA21/00030), co-financed by the European Regional Development Fund (ERDF), “A way to make Europe”; project PID2021-128862OB-I00 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE, CIBER de Salud Mental-Instituto de Salud Carlos III (project number CB07/09/0031); Delegación del Gobierno para el Plan Nacional sobre Drogas (project number 2017/085, 2022/008917); and Fundación Alicia Koplowitz. D.R.-M. was supported by Consejería de Educación e investigación, Comunidad de Madrid, co-funded by the European Social Fund “Investing in your future” (grant, PEJD-2018-PRE/BMD-7899). M.C.-V. was supported by a predoctoral grant from Fundación Tatiana Pérez de Guzmán el Bueno. N.L.-R. was supported by the Instituto de investigación Sanitaria Gregorio Marañón, “Programa Intramural de Impulso a la I+D+I 2019”. V.G.-R was supported by Consejería de Educación e investigación, Comunidad de Madrid, co-funded by the European Social Fund “Investing in your future” (grant, PEJD-2017-TL/BMD-7385). C.G.-R. was supported by Universidad Rey Juan Carlos (PREDOC20-054). R.A. was supported by Ministerio de Ciencia, Innovación y Universidades (grant number PID2019-111510RB-I00) and Grupo Español de Motilidad Digestiva (Beca Allergan, 2017). M.D. work was supported by Ministerio de Ciencia e Innovación (MCIN) and Instituto de Salud Carlos III (PT20/00044). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (SEV-2015-0505). J.F. was supported by “Contrato Intramural Postdoctoral” from FINBA (Principado de Asturias, Spain). F.L. was supported by Ayudas para grupos de investigación de organismos del Principado de Asturias (SV-PA-21-AYUD/2021/51347)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Prenatal omega-3 fatty acids supplementation mitigates some schizophrenia-like deficits in offspring: A PET and MRI study in a rat model

  • Diego Romero-Miguel
  • Marta Casquero-Veiga
  • Nicolás Lamanna-Rama
  • Raquel Chávez-Valencia
  • Vanessa Gómez-Rangel
  • Ravit Hadar
  • Christine Winter
  • Manuel Desco
  • María Luisa Soto-Montenegro
Omega-3 fatty acids (OM) have been employed as adjunctive therapy in patients with schizophrenia, but their potential as a preventive strategy remains unclear. This study aims to evaluate whether dietary OM supplementation during pregnancy may prevent schizophrenia-like deficits in a maternal immune stimulation (MIS) model. Pregnant Wistar rats were injected with PolyI:C (i.e. MIS) or Saline on gestational day 15. They were fed with OM-enriched chow, either from MIS until delivery (OM7) or throughout gestation (OM21). Two control groups (Saline-naïve & MIS-naïve) were maintained on standard chow. In adulthood, offspring were assessed through tests for locomotion, anxiety and short- and long-term memory (STM, LTM). Brain glucose metabolism and structural in vivo neuroimaging studies were performed using PET and MRI techniques. OM7/OM21 treatments prevented the hyperlocomotion in MIS-offspring while STM deficits were only improved by OM7. Both OM7/OM21 treatments prevented certain metabolic and volumetric changes in the cortex, as well as the enlargement of the ventricles. Additionally, OM21 protected WM integrity in MIS-offspring. Altogether, our study highlights the potential of prenatal OM dietary supplementation to ameliorate some of the SCZ-like deficits observed in the MIS model., MLS was supported by the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III (project number PI17/01766, and grant number BA21/00030), co-financed by the European Regional Development Fund (ERDF), “A way to make Europe”; project PID2021-128862OB-I00 funded by MCIN /AEI /10.13039/501100011033 / FEDER, UE; CIBER de Salud Mental - Instituto de Salud Carlos III (project number CB07/ 09/0031); Delegación del Gobierno para el Plan Nacional sobre Drogas (project number 2017/085, 2024I090); and Delegacion del Gobierno para el Plan Nacional sobre Drogas correspondiente a fondos del Mecanismo de Recuperacion, Transformacion y Resiliencia de la Union Europea (EXP2022/008917). DRM was supported by Consejería de Educación e investigación, Comunidad de Madrid, co-funded by the European Social Fund “Investing in your future” (grant, PEJD-2018-PRE/BMD-7899). MCV was supported by a predoctoral grant from Fundación Tatiana Pérez de Guzmán el Bueno. NLR was supported by the Instituto de investigación Sanitaria Gregorio Marañón, “Programa Intramural de Impulso a la I + D + I 2019”. MD work was supported by Ministerio de Ciencia e Innovación (MCIN) and Instituto de Salud Carlos III (PT23/00027). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505)., Peer reviewed